Skip to main content

Advertisement

Table 2 SF-12v2 and SIBDQ scores for the acute phase sample at acute phase visits

From: Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

   Baseline Week 8 Change
N LS Mean SE LS Mean SE LS Mean Difference (95% CI) Effect size dz, (95% CI)
SF-12v2
 Physical functioning 673 46.3 0.36 51.0 0.34 4.6‡ (3.7, 5.6) 0.41 (0.32, 0.49)
 Role physical 673 43.8 0.32 49.4 0.30 5.6‡ (4.7, 6.5) 0.61 (0.52, 0.70)
 Bodily pain 673 43.5 0.37 51.6 0.33 8.1‡ (7.2, 9.1) 0.74 (0.63, 0.83)
 General health 674 41.6 0.40 48.8 0.37 7.3‡ (6.2, 8.3) 0.63 (0.54, 0.73)
 Vitality 672 46.8 0.38 53.2 0.39 6.4‡ (5.3, 7.5) 0.53 (0.43, 0.61)
 Social functioning 674 42.5 0.37 49.2 0.35 6.8‡ (5.8, 7.8) 0.63 (0.53, 0.71)
 Role emotional 673 41.9 0.38 47.5 0.37 5.6‡ (4.6, 6.6) 0.49 (0.39, 0.58)
 Mental health 674 44.2 0.38 50.8 0.39 6.6‡ (5.5, 7.6) 0.56 (0.47, 0.65)
 PCS 673 44.9 0.31 50.8 0.28 5.9‡ (5.1, 6.8) 0.65 (0.55, 0.74)
 MCS 674 43.2 0.37 49.5 0.36 6.4‡ (5.3, 7.4) 0.58 (0.49, 0.66)
SIBDQ
 Bowel symptoms 602 12.6 0.13 16.7 0.15 4.1‡ (3.7, 4.5) 1.00 (0.88, 1.10)
 Systemic symptoms 602 8.9 0.11 10.9 0.11 2.0‡ (1.7, 2.3) 0.68 (0.57, 0.77)
 Emotional function 602 12.8 0.17 16.1 0.17 3.2‡ (2.8, 3.7) 0.74 (0.64, 0.86)
 Social function 601 9.0 0.13 11.6 0.12 2.6‡ (2.3, 3.0) 0.77 (0.66, 0.86)
 Total score 600 43.3 0.45 55.3 0.49 12.0‡ (10.7, 13.3) 0.92 (0.80, 1.02)
  1. CI confidence interval, LS least squares, MCS mental component summary, PCS physical component summary, SE standard error, SF-12v2 SF-12v2 Health Survey, SIBDQ Short Inflammatory Bowel Disease Questionnaire
  2. Findings for each outcome are based on mixed-effects models for repeated measures with subject as a random effect and visit as a fixed effect
  3. Week 8 includes early withdrawal visits during the acute phase
  4. P < 0.001